Vasculopathy in patients with Fabry disease: Current controversies and research directions

Molecular Genetics and Metabolism

Volumn 99, Issue 2, 2010, Pages 99-108

  Rombach, S M ^a   Twickler, Th B ^a   Aerts, J M F G ^a   Linthorst, G E ^a   Wijburg, F A ^a   Hollak, C E M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Fabry disease; Vascular complications; Vasculopathy

Indexed keywords

ANGIOTENSIN II; CELL ADHESION MOLECULE; CYTOKINE; NITRIC OXIDE;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL WALL; CLINICAL FEATURE; CYTOKINE PRODUCTION; DIAGNOSTIC IMAGING; ENDOTHELIUM CELL; ENZYME ACTIVITY; FABRY DISEASE; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INTIMA; LEUKOCYTE; MEDICAL RESEARCH; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ADULT; AGED; BIOMEDICAL RESEARCH; BLOOD VESSELS; DIAGNOSTIC IMAGING; ENDOTHELIUM; FABRY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; THROMBOSIS;

EID: 73749088671     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.10.004     Document Type: Review

References (113)

1. Brady R.O., Gal A.E., Bradley R.M., Martensson E., Warshaw A.L., and Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N. Engl. J. Med. 276 (1967) 1163-1167
2. Kint J.A. Fabry's disease: alpha-galactosidase deficiency. Science 167 (1970) 1268-1269
3. R.J. Desnick, Y.A. Ioannou, M.E. Eng, α-Galactosidase A deficiency: Fabry disease. In: C.R. Scriver, A.L.S.W. Beaudet, D. Valle (Eds.), The metabolic and molecular bases of inherited disease, eighth ed., McGraw-Hill, New York, 2001, pp. 3733-3774.
4. Moore D.F., Kaneski C.R., Askari H., and Schiffmann R. The cerebral vasculopathy of Fabry disease. J. Neurol. Sci. 257 (2007) 258-263
5. Schiffmann R. Fabry disease. Pharmacol. Ther. 122 (2009) 65-77
6. Rolfs A., Bottcher T., Zschiesche M., Morris P., Winchester B., Bauer P., Walter U., Mix E., Lohr M., Harzer K., Strauss U., Pahnke J., Grossmann A., and Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366 (2005) 1794-1796
7. Sessa A., Meroni M., Battini G., Maglio A., Brambilla P.L., Bertella M., Nebuloni M., Pallotti F., Giordano F., Bertagnolio B., and Tosoni A. Renal pathological changes in Fabry disease. J. Inherit. Metab. Dis. 24 Suppl. 2 (2001) 66-70
8. Kampmann C., Wiethoff C.M., Perrot A., Beck M., Dietz R., and Osterziel K.J. The heart in Anderson Fabry disease. Z. Kardiol. 91 (2002) 786-795
9. Desnick R.J., Brady R., Barranger J., Collins A.J., Germain D.P., Goldman M., Grabowski G., Packman S., and Wilcox W.R. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann. Intern. Med. 138 (2003) 338-346
10. Barbey F., Brakch N., Linhart A., Rosenblatt-Velin N., Jeanrenaud X., Qanadli S., Steinmann B., Burnier M., Palecek T., Bultas J., and Hayoz D. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 839-844
11. Schiffmann R., Kopp J.B., Austin III H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., and Brady R.O. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285 (2001) 2743-2749
12. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., and Desnick R.J. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N. Engl. J. Med. 345 (2001) 9-16
13. Wilcox W.R., Banikazemi M., Guffon N., Waldek S., Lee P., Linthorst G.E., Desnick R.J., and Germain D.P. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 75 (2004) 65-74
14. Weidemann F., Niemann M., Breunig F., Herrmann S., Beer M., Stork S., Voelker W., Ertl G., Wanner C., and Strotmann J. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119 (2009) 524-529
15. Germain D.P., Waldek S., Banikazemi M., Bushinsky D.A., Charrow J., Desnick R.J., Lee P., Loew T., Vedder A.C., Abichandani R., Wilcox W.R., and Guffon N. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 18 (2007) 1547-1557
16. Vedder A.C., Linthorst G.E., Houge G., Groener J.E., Ormel E.E., Bouma B.J., Aerts J.M., Hirth A., and Hollak C.E. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2 (2007) e598
17. Tondel C., Bostad L., Hirth A., and Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am. J. Kidney Dis. 51 (2008) 767-776
18. Tosoni A., Nebuloni M., Zerbi P., Vago L., Comotti C., and Sessa A. Ultrastructural study of renal involvement in two females with Anderson-Fabry disease. Ultrastruct. Pathol. 29 (2005) 203-207
19. Svarstad E., Bostad L., Kaarboe O., Houge G., Tondel C., Lyngdal P.T., and Iversen B.M. Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry's disease. Clin. Nephrol. 63 (2005) 394-401
20. Meehan S.M., Junsanto T., Rydel J.J., and Desnick R.J. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications. Am. J. Kidney Dis. 43 (2004) 164-171
21. Thurberg B.L., Rennke H., Colvin R.B., Dikman S., Gordon R.E., Collins A.B., Desnick R.J., and O'Callaghan M. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 62 (2002) 1933-1946
22. Eng C.M., Banikazemi M., Gordon R.E., Goldman M., Phelps R., Kim L., Gass A., Winston J., Dikman S., Fallon J.T., Brodie S., Stacy C.B., Mehta D., Parsons R., Norton K., O'Callaghan M., and Desnick R.J. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 68 (2001) 711-722
23. Friedlaender M.M., Kopolovic J., Rubinger D., Silver J., Drukker A., Ben Gershon Z., Durst A.L., and Popovtzer M.M. Renal biopsy in Fabry's disease eight years after successful renal transplantation. Clin. Nephrol. 27 (1987) 206-211
24. Burkholder P.M., Updike S.J., Ware R.A., and Reese O.G. Clinicopathologic, enzymatic, and genetic features in a case of Fabry's disease. Arch. Pathol. Lab. Med. 104 (1980) 17-25
25. Taylor I., Dennett X., Nicholls K., and Tubridy N. Intermittent claudication-atypical presentation diagnosis and treatment. J. Clin. Neurosci. 11 (2004) 783-785
26. Jardine D.L., Fitzpatrick M.A., Troughton W.D., and Tie A.B. Small bowel ischaemia in Fabry's disease. J. Gastroenterol. Hepatol. 9 (1994) 201-204
27. Schiffmann R., Rapkiewicz A., bu-Asab M., Ries M., Askari H., Tsokos M., and Quezado M. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch. 448 (2006) 337-343
28. Shirai T., Ohtake T., Kimura M., Iwata M., Fujigaki Y., Takayanagi S., Chida K., Nakamura H., Hishida A., and Irie F. Atypical Fabry's disease presenting with cholesterol crystal embolization. Intern. Med. 39 (2000) 646-649
29. Valbuena C., Carvalho E., Bustorff M., Ganhao M., Relvas S., Nogueira R., Carneiro F., and Oliveira J.P. Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy. Virchows Arch. 453 (2008) 329-338
30. Chimenti C., Morgante E., Critelli G., Russo M.A., and Frustaci A. Coronary artery bypass grafting for Fabry's disease: veins more suitable than arteries?. Hum. Pathol. 38 (2007) 1864-1867
31. Fisher E.A., Desnick R.J., Gordon R.E., Eng C.M., Griepp R., and Goldman M.E. Fabry disease: an unusual cause of severe coronary disease in a young man. Ann. Intern. Med. 117 (1992) 221-223
32. Okeda R., and Nisihara M. An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia. Neuropathology 28 (2008) 532-540
33. Takao M., Mori T., Orikasa H., Oh H., Suzuki K., Koto A., and Yamazaki K. Postmortem diagnosis of Fabry disease with acromegaly and a unique vasculopathy. Virchows Arch. 451 (2007) 721-727
34. Garzuly F., Marodi L., Erdos M., Grubits J., Varga Z., Gelpi E., Rohonyi B., Mazlo M., Molnar A., and Budka H. Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene. Brain 128 (2005) 2078-2083
35. Elleder M. Sequelae of storage in Fabry disease-pathology and comparison with other lysosomal storage diseases. Acta Paediatr. Suppl. 92 (2003) 46-53
36. Desnick R.J., Blieden L.C., Sharp H.L., Hofschire P.J., and Moller J.H. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation. 54 (1976) 818-825
37. Schatzki P.F., Kipreos B., and Payne J. Fabry's disease. Primary diagnosis by electron microscopy. Am. J. Surg. Pathol. 3 (1979) 211-219
38. Takenaka T., Teraguchi H., Yoshida A., Taguchi S., Ninomiya K., Umekita Y., Yoshida H., Horinouchi M., Tabata K., Yonezawa S., Yoshimitsu M., Higuchi K., Nakao S., Anan R., Minagoe S., and Tei C. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic echocardiographic and autopsy study. J. Cardiol. 51 (2008) 50-59
39. Hulkova H., Ledvinova J., Poupetova H., Bultas J., Zeman J., and Elleder M. [Postmortem diagnosis of Fabry disease in a female heterozygote leading to the detection of undiagnosed manifest disease in the family]. Cas. Lek. Cesk. 138 (1999) 660-664
40. Askari H., Kaneski C.R., Semino-Mora C., Desai P., Ang A., Kleiner D.E., Perlee L.T., Quezado M., Spollen L.E., Wustman B.A., and Schiffmann R. Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch. 451 (2007) 823-834
41. Fellgiebel A., Keller I., Marin D., Muller M.J., Schermuly I., Yakushev I., Albrecht J., Bellhauser H., Kinateder M., Beck M., and Stoeter P. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 72 (2009) 63-68
42. Mitsias P., and Levine S.R. Cerebrovascular complications of Fabry's disease. Ann. Neurol. 40 (1996) 8-17
43. Gupta S., Ries M., Kotsopoulos S., and Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 84 (2005) 261-268
44. Barbey F., Brakch N., Linhart A., Jeanrenaud X., Palecek T., Bultas J., Burnier M., and Hayoz D. Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatr. Suppl. 95 (2006) 63-68
45. Kovarnik T., Mintz G.S., Karetova D., Horak J., Bultas J., Skulec R., Skalicka H., Aschermann M., Elleder M., and Linhart A. Intravascular ultrasound assessment of coronary artery involvement in Fabry disease. J. Inherit. Metab. Dis. 31 (2008) 753-760
46. Jardim L., Vedolin L., Schwartz I.V., Burin M.G., Cecchin C., Kalakun L., Matte U., Aesse F., Pitta-Pinheiro C., Marconato J., and Giugliani R. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J. Inherit. Metab. Dis. 27 (2004) 229-240
47. Moon J.C., Sachdev B., Elkington A.G., McKenna W.J., Mehta A., Pennell D.J., Leed P.J., and Elliott P.M. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J. 24 (2003) 2151-2155
48. Funabashi N., Toyozaki T., Matsumoto Y., Yonezawa M., Yanagawa N., Yoshida K., and Komuro I. Images in cardiovascular medicine. Myocardial fibrosis in Fabry disease demonstrated by multislice computed tomography: comparison with biopsy findings. Circulation 107 (2003) 2519-2520
49. Eckart R.E., Kinney K.G., Belnap C.M., and Le T.D. Ventricular fibrillation refractory to automatic internal cardiac defibrillator in Fabry's disease. Review of cardiovascular manifestations. Cardiology 94 (2000) 208-212
50. Ogawa T., Kawai M., Matsui T., Seo A., Aizawa O., Hongo K., Shibata T., Yoshida S., Okamura T., Nishikawa T., and Kasajima T. Vasospastic angina in a patient with Fabry's disease who showed normal coronary angiographic findings. Jpn. Circ. J. 60 (1996) 315-318
51. Erdmann E. Angina pectoris, pathological stress EKG and a normal coronary angiogram. Internist (Berl.) 21 (1980) 165-168
52. Kalliokoski R.J., Kalliokoski K.K., Penttinen M., Kantola I., Leino A., Viikari J.S., Simell O., Nuutila P., and Raitakari O.T. Structural and functional changes in peripheral vasculature of Fabry patients. J. Inherit. Metab. Dis. 29 (2006) 660-666
53. Boutouyrie P., Laurent S., Laloux B., Lidove O., Grunfeld J.P., and Germain D.P. Non-invasive evaluation of arterial involvement in patients affected with Fabry disease. J. Med. Genet. 38 (2001) 629-631
54. Boutouyrie P., Laurent S., Laloux B., Lidove O., Grunfeld J.P., and Germain D.P. Arterial remodelling in Fabry disease. Acta Paediatr. Suppl. 91 (2002) 62-66
55. Heare T., Alp N.J., Priestman D.A., Kulkarni A.B., Qasba P., Butters T.D., Dwek R.A., Clarke K., Channon K.M., and Platt F.M. Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment. J. Inherit. Metab. Dis. 30 (2007) 79-87
56. Moore D.F., Altarescu G., Pursley R., Campia U., Panza J.A., Dimitriadis E., and Schiffmann R. Arterial wall properties and Womersley flow in Fabry disease. BMC Cardiovasc. Disord. 2 (2002) 1
57. Kalliokoski R.J., Kalliokoski K.K., Sundell J., Engblom E., Penttinen M., Kantola I., Raitakari O.T., Knuuti J., and Nuutila P. Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J. Inherit. Metab. Dis. 28 (2005) 563-573
58. Puccio D., Coppola G., Corrado E., Muratori I., Pistone G., Buongiorno M.R., Arico M., and Novo S. Non invasive evaluation of endothelial function in patients with Anderson-Fabry disease. Int. Angiol. 24 (2005) 295-299
59. Stemper B., and Hilz M.J. Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease. J. Neurol. 250 (2003) 970-976
60. Seino Y., Vyden J.K., Philippart M., Rose H.B., and Nagasawa K. Peripheral hemodynamics in patients with Fabry's disease. Am. Heart J. 105 (1983) 783-787
61. Martin L., Sturgess A., Sillence D., and Murrell D.F. Fabry disease in a heterozygote presenting as hand ischaemia and painful acroparaesthesia. Australas. J. Dermatol. 48 (2007) 40-42
62. Dimitrow P.P., Krzanowski M., and Undas A. Reduced coronary flow reserve in Anderson-Fabry disease measured by transthoracic Doppler echocardiography. Cardiovasc. Ultrasound. 3 (2005) 11
63. Altarescu G., Moore D.F., Pursley R., Campia U., Goldstein S., Bryant M., Panza J.A., and Schiffmann R. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 32 (2001) 1559-1562
64. Park J.L., Whitesall S.E., D'Alecy L.G., Shu L., and Shayman J.A. Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin. Exp. Pharmacol. Physiol. 35 (2008) 1156-1163
65. Park J.L., Shu L., and Shayman J.A. Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse. Am. J. Physiol. Heart Circ. Physiol. 296 (2009) H1133-H1140
66. Hilz M.J., Kolodny E.H., Brys M., Stemper B., Haendl T., and Marthol H. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J. Neurol. 251 (2004) 564-570
67. Moore D.F., Altarescu G., Ling G.S., Jeffries N., Frei K.P., Weibel T., Charria-Ortiz G., Ferri R., Arai A.E., Brady R.O., and Schiffmann R. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33 (2002) 525-531
68. Itoh Y., Esaki T., Cook M., Qasba P., Shimoji K., Alroy J., Brady R.O., Sokoloff L., and Moore D.F. Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease. J. Neurochem. 79 (2001) 1217-1224
69. Moore D.F., Scott L.T., Gladwin M.T., Altarescu G., Kaneski C., Suzuki K., Pease-Fye M., Ferri R., Brady R.O., Herscovitch P., and Schiffmann R. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104 (2001) 1506-1512
70. Moore D.F., Herscovitch P., and Schiffmann R. Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J. Neuroimaging. 11 (2001) 303-307
71. Crutchfield K.E., Patronas N.J., Dambrosia J.M., Frei K.P., Banerjee T.K., Barton N.W., and Schiffmann R. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50 (1998) 1746-1749
72. Grewal R.P. Stroke in Fabry's disease. J. Neurol. 241 (1994) 153-156
73. Ritter M., Dittrich R., and Droste D.W. Microembolus detection in four patients with Fabry's disease: further support for a primarily microangiopathic origin of early cerebrovascular symptoms. Eur. Neurol. 50 (2003) 141-145
74. Utsumi K., Ueda K., Watanabe M., Sakamaki M., Arii K., Yamazaki M., Komaba Y., Katsura K.I., Iino Y., and Katayama Y. Thrombosis in Japanese patients with Fabry disease. J. Neurol. Sci. 283 (2009) 83-85
75. Andersen M.V., Dahl H., Fledelius H., and Nielsen N.V. Central retinal artery occlusion in a patient with Fabry's disease documented by scanning laser ophthalmoscopy. Acta Ophthalmol. (Copenh.) 72 (1994) 635-638
76. Sher N.A., Reiff W., Letson R.D., and Desnick R.J. Central retinal artery occlusion complicating Fabry's disease. Arch. Ophthalmol. 96 (1978) 815-817
77. Shen Y., Bodary P.F., Vargas F.B., Homeister J.W., Gordon D., Ostenso K.A., Shayman J.A., and Eitzman D.T. Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation. Stroke 37 (2006) 1106-1108
78. Eitzman D.T., Bodary P.F., Shen Y., Khairallah C.G., Wild S.R., Abe A., Shaffer-Hartman J., and Shayman J.A. Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J. Am. Soc. Nephrol. 14 (2003) 298-302
79. Kumagai K., Mitamura Y., Mizunoya S., Fujimoto N., and Yamamoto S. A case of anterior ischemic optic neuropathy associated with Fabry's disease. Jpn. J. Ophthalmol. 52 (2008) 421-423
80. Guenoun J.M., Parc C., Monnet D., and Brezin A.P. Loss of visual acuity due to choroidal ischemia in Fabry's disease. J. Fr. Ophtalmol. 26 (2003) 842-844
81. Dantas M.A., Fonseca R.A., Kaga T., Yannuzzi L.A., and Spaide R.F. Retinal and choroidal vascular changes in heterozygous Fabry disease. Retina 21 (2001) 87-89
82. Abe H., Sakai T., Sawaguchi S., Hasegawa S., Takagi M., Yoshizawa T., Usui T., and Horikawa Y. Ischemic optic neuropathy in a female carrier with Fabry's disease. Ophthalmologica 205 (1992) 83-88
83. Ohkubo H. Several functional and fluorescein fundus angiographic findings in Fabry's disease. Ophthalmologica 196 (1988) 132-136
84. DeGraba T., Azhar S., Dignat-George F., Brown E., Boutiere B., Altarescu G., McCarron R., and Schiffmann R. Profile of endothelial and leukocyte activation in Fabry patients. Ann. Neurol. 47 (2000) 229-233
85. Demuth K., and Germain D.P. Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr. Suppl. 91 (2002) 57-61
86. Shen J.S., Meng X.L., Moore D.F., Quirk J.M., Shayman J.A., Schiffmann R., and Kaneski C.R. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol. Genet. Metab. 95 (2008) 163-168
87. Gelderman M.P., Schiffmann R., and Simak J. Elevated endothelial microparticles in Fabry children decreased after enzyme replacement therapy. Arterioscler. Thromb. Vasc. Biol. 27 (2007) e138-e139
88. Vedder A.C., Biro E., Aerts J.M., Nieuwland R., Sturk G., and Hollak C.E. Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment. Nephrol. Dial. Transplant. 24 (2009) 3074-3081
89. Fedi S., Gensini F., Gori A.M., Abbate R., and Borsini W. Homocysteine and tissue factor pathway inhibitor levels in patients with Fabry's disease. J. Thromb. Haemost. 3 (2005) 2117-2119
90. Moore D.F., Ye F., Brennan M.L., Gupta S., Barshop B.A., Steiner R.D., Rhead W.J., Brady R.O., Hazen S.L., and Schiffmann R. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J. Magn. Reson. Imaging 20 (2004) 674-683
91. Kaneski C.R., Moore D.F., Ries M., Zirzow G.C., and Schiffmann R. Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. Neurology 67 (2006) 2045-2047
92. Heltianu C., Costache G., Azibi K., Poenaru L., and Simionescu M. Endothelial nitric oxide synthase gene polymorphisms in Fabry's disease. Clin. Genet. 61 (2002) 423-429
93. Heltianu C., Costache G., Gafencu A., Diaconu M., Bodeanu M., Cristea C., Azibi K., Poenaru L., and Simionescu M. Relationship of eNOS gene variants to diseases that have in common an endothelial cell dysfunction. J. Cell. Mol. Med. 9 (2005) 135-142
94. Vedder A.C., Linthorst G.E., van Breemen M.J., Groener J.E., Bemelman F.J., Strijland A., Mannens M.M., Aerts J.M., and Hollak C.E. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J. Inherit. Metab. Dis. 30 (2007) 68-78
95. MacDermot K.D., Holmes A., and Miners A.H. Natural history of Fabry disease in affected males and obligate carrier females. J. Inherit. Metab. Dis. 24 Suppl. 2 (2001) 13-14
96. Schiffmann R., Warnock D.G., Banikazemi M., Bultas J., Linthorst G.E., Packman S., Sorensen S.A., Wilcox W.R., and Desnick R.J. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol. Dial. Transplant. 24 (2009) 2101-2111
97. MacDermot K.D., Holmes A., and Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J. Med. Genet. 38 (2001) 769-775
98. Thurberg B.L., Randolph B.H., Granter S.R., Phelps R.G., Gordon R.E., and O'Callaghan M. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J. Invest. Dermatol. 122 (2004) 900-908
99. Thurberg B.L., Fallon J.T., Mitchell R., Aretz T., Gordon R.E., and O'Callaghan M.W. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 119 (2009) 2561-2567
100. Breunig F., and Wanner C. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy. J. Nephrol. 21 (2008) 32-37
101. N. Brakch, O. Dormond, S. Bekri, D. Golshayan, M. Correvon, L. Mazzolai, B. Steinmann, F. Barbey, Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease, Eur. Heart J. (2009). Epub ahead of print.
102. Aerts J.M., Groener J.E., Kuiper S., Donker-Koopman W.E., Strijland A., Ottenhoff R., van R.C., Mirzaian M., Wijburg F.A., Linthorst G.E., Vedder A.C., Rombach S.M., Cox-Brinkman J., Somerharju P., Boot R.G., Hollak C.E., Brady R.O., and Poorthuis B.J. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. USA 105 (2008) 2812-2817
103. Bodary P.F., Shen Y., Vargas F.B., Bi X., Ostenso K.A., Gu S., Shayman J.A., and Eitzman D.T. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111 (2005) 629-632
104. Vedder A.C., Gerdes V.E., Poorthuis B.J., Helmond M., Trip M.D., Aerts J.M., and Hollak C.E. Failure to detect Fabry patients in a cohort of prematurely atherosclerotic males. J. Inherit. Metab. Dis. 30 (2007) 988
105. Buja L.M. Evaluation of recombinant alpha-galactosidase A therapy for amelioration of the cardiovascular manifestations of Fabry disease: an important role for endomyocardial biopsy. Circulation 119 (2009) 2539-2541
106. Doran A.C., Meller N., and McNamara C.A. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 812-819
107. Dandona P., Dhindsa S., Ghanim H., and Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J. Hum. Hypertens. 21 (2007) 20-27
108. de Cavanagh E.M., Ferder M., Inserra F., and Ferder L. Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am. J. Physiol. Heart. Circ. Physiol. 296 (2009) H550-H558
109. Brillante D.G., O'Sullivan A.J., Johnstone M.T., and Howes L.G. Evidence for functional expression of vascular angiotensin II type 2 receptors in patients with insulin resistance. Diab. Obes. Metab. 10 (2008) 143-150
110. Drummond P.D. The effect of noradrenaline, angiotensin II and vasopressin on blood flow and sensitivity to heat in capsaicin-treated skin. Clin. Auton. Res. 8 (1998) 87-93
111. Shu L., Park J.L., Byun J., Pennathur S., Kollmeyer J., and Shayman J.A. Decreased nitric oxide bioavailability in a mouse model of Fabry disease. J. Am. Soc. Nephrol. 20 (2009) 1975-1985
112. Friedman G.S., Wik D., Silva L., Abdou J.C., Meier-Kriesche H.U., Kaplan B., Bonomini L., DeFranco P., Lyman N., Mulgaonkar S., and Jacobs M. Allograft loss in renal transplant recipients with Fabry's disease and activated protein C resistance. Transplantation 69 (2000) 2099-2102
113. McCormick M.L., Gavrila D., and Weintraub N.L. Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 461-469